Catecholaminergic polymorphic ventricular tachycardia: from bench to bedside
Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome or so-called 'channelopathy'. CPVT is characterised by the occurrence of adrenergic mediated polymorphic ventricular tachyarrhythmias (figure 1). 1 The prevalence of CPVT in the general population is unknown, but has been estimated at 1 in 10 000. Although a rare disease, recognition of CPVT is important because of its high mortality rate of up to 50% in severely affected untreated individuals up to the age of 20 years. 1 Accordingly, CPVT probably plays a significant role in autopsy negative, sudden unexplained death of young individuals, (w1) and sudden infant death syndrome (ie, sudden death of an infant under 1 year of age that remains unexplained after a death scene and medicolegal investigation, including a complete autopsy and clinical history review). 2 For the last 15 years, significant progress has been made in our understanding of genetic, pathophysiological, and clinical aspects of CPVT. The aim of this article is to offer a perspective on molecular genetics, disease pathogenesis, clinical and genetic diagnosis, therapeutic strategies, and prognosis in CPVKeywords
This publication has 19 references indexed in Scilit:
- Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in humanHuman Molecular Genetics, 2012
- Dantrolene rescues arrhythmogenic RYR2 defect in a patient‐specific stem cell model of catecholaminergic polymorphic ventricular tachycardiaEMBO Molecular Medicine, 2012
- Flecainide Therapy Reduces Exercise-Induced Ventricular Arrhythmias in Patients With Catecholaminergic Polymorphic Ventricular TachycardiaJACC, 2011
- The RYR2-Encoded Ryanodine Receptor/Calcium Release Channel in Patients Diagnosed Previously With Either Catecholaminergic Polymorphic Ventricular Tachycardia or Genotype Negative, Exercise-Induced Long QT SyndromeJACC, 2009
- Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humansNature Medicine, 2009
- Left Cardiac Sympathetic Denervation for Catecholaminergic Polymorphic Ventricular TachycardiaNew England Journal of Medicine, 2008
- A mechanism for sudden infant death syndrome (SIDS): Stress-induced leak via ryanodine receptorsHeart Rhythm, 2007
- Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardiaHeart Rhythm, 2006
- A Missense Mutation in a Highly Conserved Region of CASQ2 Is Associated with Autosomal Recessive Catecholamine-Induced Polymorphic Ventricular Tachycardia in Bedouin Families from IsraelThe American Journal of Human Genetics, 2001
- Arrhythmic disorder mapped to chromosome 1q42–q43 causes malignant polymorphic ventricular tachycardia in structurally normal heartsJACC, 1999